Publication & Citation Trends
Publications
0 total
ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib OA
Cited by 86
Semantic Scholar
Discovery of Novel UDP-N-Acetylglucosamine Acyltransferase (LpxA) Inhibitors with Activity against Pseudomonas aeruginosa.
Cited by 20
Semantic Scholar
Pharmacokinetics-Pharmacodynamics of Enmetazobactam Combined with Cefepime in a Neutropenic Murine Thigh Infection Model OA
Cited by 31
Semantic Scholar
Differential activity of ATR and WEE1 inhibitors in a highly sensitive subpopulation of DLBCL linked to replication stress. OA
Cited by 52
Semantic Scholar
pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry OA
Cited by 34
Semantic Scholar
Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice OA
Cited by 47
Semantic Scholar
Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent. OA
Cited by 249
Semantic Scholar
Abstract B32: CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, combined with DDR agents provides a novel approach to increasing therapeutic index
Cited by 1
Semantic Scholar
Research Topics
Cancer-related Molecular Pathways
(25)
Microtubule and mitosis dynamics
(22)
Semiconductor materials and devices
(18)
PARP inhibition in cancer therapy
(18)
Glioma Diagnosis and Treatment
(17)
Affiliations
AstraZeneca (United Kingdom)
University of London
The Pirbright Institute
Roche (United States)
Royal Veterinary College